Holen Sie sich die Stockscreener-App
3.31
0.30%
0.01
Handel nachbörslich:
3.30
-0.01
-0.30%
Neonc Technologies Holdings Inc Aktie (NTHI) Neueste Nachrichten
NeOnc Technologies Initiated at Buy by Roth Capital - Moomoo
NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst - The Manila Times
NeOnc Technologies Holdings Gains Roth Capital Coverage as NEO100 and NEO212 Advance Toward Key Clinical and Regulatory Milestones - Quiver Quantitative
Roth Capital Initiates NeOnc Technologies at Buy - marketscreener.com
NeOnc Technologies stock initiated with buy rating at Roth/MKM - Investing.com
NeOnc Technologies stock initiated with buy rating at Roth/MKM By Investing.com - Investing.com Canada
NeOnc Technologies Holdings, Inc. (NTHI) Stock Price, News, Quote & History - Yahoo! Finance Canada
NeOnc Technologies Reports Encouraging Phase 2a NEO100 Results in IDH1-Mutant High-Grade Glioma - Quiver Quantitative
NeOnc’s Delivery may Finally Change the Equation for Brain Cancer’s Next Frontier - marketscreener.com
Nearly half of patients were progression-free at six months. NeOnc plans FDA talks. - Stock Titan
[8-K] NEONC TECHNOLOGIES HOLDINGS, INC. Reports Material Event - Stock Titan
NeOnc Technologies Holdings’ NEO100 Phase 2a Glioma Results Highlight Intranasal Brain Cancer Delivery Approach - Quiver Quantitative
NeOnc Charting New Nasal Route to Treating Brain Cancer - GlobeNewswire
In a 24-patient study, 48.9% were progression-free at six months with a nose-delivered brain cancer treatment. - stocktitan.net
Neonc Technologies CFO sells $16,809 in company stock By Investing.com - Investing.com South Africa
Neonc Technologies CFO sells $16,809 in company stock - Investing.com
NeOnc Technologies (NTHI) CFO sells shares under preset plan - stocktitan.net
NeOnc redeems $6M preferred stock with cash from recent offering - Investing.com Nigeria
NeOnc Technologies Redeems All Series A Preferred Shares, Eliminating Potential Dilution and Advancing CNS Pipeline - Quiver Quantitative
In a brain-cancer trial, 48.9% had no worsening at six months. NeOnc also redeemed $6M in stock. - Stock Titan
NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution - marketscreener.com
A $6 million payment kept NeOnc from issuing new shares - Stock Titan
NeOnc CEO purchases additional shares following trial results By Investing.com - Investing.com South Africa
NEONC TECHNOLOGIES HOLDINGS (NASDAQ: NTHI) CFO Garnett Keithly Acquires 257 Shares at $3.89 Each - Kalkine Media
NeOnc’s $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA - The Manila Times
NeOnc CEO purchases additional shares following trial results - Investing.com
An experimental brain-cancer treatment reached 48.9% at six months, versus a 20% benchmark - Stock Titan
Press Release: NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results - Moomoo
Neonc technologies CEO Thomas Chen buys $39,999 in stock By Investing.com - Investing.com South Africa
Neonc CFO Keithly Garnett buys $1,000 in company stock By Investing.com - Investing.com Nigeria
Neonc technologies CEO Thomas Chen buys $39,999 in stock - Investing.com
Neonc technologies CEO Amir Heshmatpour acquires $174,795 in stock By Investing.com - Investing.com UK
NeOnc Technologies (NTHI) CEO is buying more of his own stock - Stock Titan
NeOnc Technologies (NTHI) CFO adds shares in open-market buy - Stock Titan
NeOnc Technologies (NTHI) insider may sell $18,900 in stock - Stock Titan
Investor Determination to Beat Cancer Puts NeOnc’s Novel Therapies and Patented Platform in Focus - marketscreener.com
48.9% had no cancer progression at six months in NeOnc’s 24-person study - Stock Titan
Neonc technologies CEO Amir Heshmatpour acquires $174,795 in stock - Investing.com
NeOnc Technologies Holdings CEO Buys More Shares After Promising Phase 2a NEO100 Data and Ahead of FDA Meeting - Quiver Quantitative
Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test - marketscreener.com
Neonc Technologies CEO Amir Heshmatpour buys $135,619 in shares By Investing.com - Investing.com Nigeria
Neonc Technologies CEO Amir Heshmatpour buys $135,619 in shares - Investing.com
NeOnc (NTHI) CEO now holds 3.13M shares after stock buy - Stock Titan
Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer - marketscreener.com
Form 8K Neonc Technologies Holdings Inc For: 10 September By Investing.com - Investing.com Nigeria
NeOnc raises USD 15m to advance Phase II CNS cancer programs after NEO100 efficacy readout - AllSci
NeOnc Technologies Launches $15 Million Registered Direct Offering at $4.20 With Warrants - TradingView
NeOnc Technologies Company Profile & Introduction - Moomoo
NeOnc Technologies prices $15M registered direct offering By Investing.com - Investing.com Nigeria
NeOnc Technologies Holdings Secures $15 Million Registered Direct Offering After Positive Phase 2a Data and Insider Buying - Quiver Quantitative
NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data - marketscreener.com
NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors - Stocktwits
NeOnc Technologies prices $15M registered direct offering - investing.com
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):